Lynch Carpenter Investigates Claims in Ascension Health Data Breach
PITTSBURGH, May 06, 2025 (GLOBE NEWSWIRE) -- Ascension Health ('Ascension') recently announced a cybersecurity incident, which impacted the personal information of thousands of individuals. The information potentially impacted in the data breach includes individuals' names, addresses, phone numbers, dates of birth, email addresses, race/gender, Social Security numbers, medical record numbers, insurance company names, and other health information.
Lynch Carpenter, LLP is investigating claims against Ascension related to this data breach. If you received a data breach notification from Ascension, you may be entitled to compensation. Please fill out this form so that an attorney can review your case.
About Lynch Carpenter
Lynch Carpenter is a national class action law firm with offices in Pennsylvania, California, and Illinois. Our firm has represented millions of clients in data privacy matters for more than a decade and has earned national acclaim for complex litigation for plaintiffs across the country. To learn more, please visit www.lynchcarpenter.com .
For more information, please call Patrick Donathen at (412) 322-9243, or email him at [email protected] .
CONTACT Patrick Donathen
COMPANY Lynch Carpenter LLP
PHONE (412) 322-9243
EMAIL [email protected]
WEB lynchcarpenter.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
After losing lawsuit, the family of Grace Schara plans to continue telling her story
Despite a trial verdict in favor of Ascension, the family of 19-year-old Grace Schara, who died at an Appleton hospital in 2021, vows to continue fighting what they say is a David-and-Goliath battle against the country's healthcare system. "This door has been closed, but when God closes one door, he always opens another," Grace's father Scott Schara said at a news conference June 20, held on the front yard of a home in Appleton where Schara's attorneys stayed during the trial. Grace died Oct. 13, 2021 at Ascension NE Wisconsin-St. Elizabeth Hospital, seven days after she was admitted for symptoms of COVID-19. While her cause of death was listed as "acute respiratory failure with hypoxia as a result of COVID-19 pneumonia," Scott Schara filed a lawsuit claiming Grace actually died of a lethal concoction of drugs administered to her by hospital staff, then was not saved due to a wrongful do-not-resuscitate order. For years, the Schara family has worked to bring attention to their daughter's death, with billboards along Interstate 41 and other highways, as well as a website and newsletter. The trial came more than two years after the family's lawsuit was filed in Outagamie County Circuit Court. At the end of the nearly three-week trial, a 12-person jury deliberated for two hours and came to a verdict June 19 in favor of the hospital. Of the 13 claims the jury answered in the verdict, only two claims had a dissenter — and there was only one dissenter for each of the two claims. Cindy Schara, Grace's mother, said the verdict was heartbreaking. "We really did expect the jury to see what they did to Grace," she said. "She was a valuable person in this world. ... This jury, deliberating as quickly as they did in coming up with their verdict, did not give Grace the respect that she deserved." RELATED: COVID, conspiracy theories and a billboard campaign: Grace Schara's hospital death finally sees trial While the family's attorneys argued that Grace died of a drug overdose at the hands of medical staff, attorneys for Ascension and defendants Dr. Gavin Shokar and nurse Hollee McInnis, who both cared for Grace in her final days, gave a different version of events. The defendants' attorneys argued that the drugs provided to Grace — precedex, lorazepam and morphine — were routinely provided in hospital intensive care units, and were used in responsible dosages as a way to slow Grace's too-fast breathing to allow her to take in more oxygen. Shokar testified during the trial that Grace's parents had explicitly said they did not want her to be intubated, which he said would have been the last-case option he had to try to save her life. Shokar said he labeled Grace as both do not intubate and do not resuscitate with Grace's family's consent, after extensive conversations about the futility of CPR when Grace's lungs were not working properly. The Scharas say differently, claiming they had no knowledge of Grace's do-not-resuscitate status until her heart stopped and medical staff did nothing to try to revive her, despite the family's shouts and begging. Besides Scott and Cindy, other speakers at the news conference were Grace's sister, Jess Vander Heiden, as well as attorneys Joseph Voiland and Warner Mendenhall. Gathered in the front yard and sidewalk were around two dozen supporters, many of whom wore purple shirts memorializing Grace. Scott, Cindy and Jess all expressed disappointment with the outcome of the trial, but said they rely on their faith to guide them as they move forward. "We are trusting that God has this play out the way that He had known it was going to play out," Cindy said. The Scharas shared some details about the process to bring the case to trial, and thanked the attorneys for their work. They acknowledged many odds stacked against people taking on lawsuits against the medical system — including that the maximum amount a person can be awarded for non-economic damages in a medical malpractice lawsuit in Wisconsin is $750,000, and the case took "just over a million dollars to bring to trial," Scott said. Scott also discussed some of his beliefs at the news conference, including that hospitals were inclined to not save COVID-19 patients due to monetary incentives, and that people should avoid going to hospitals whenever possible. At trial, defense attorneys pointed out some of Scott's beliefs in conspiracies — something the Scharas said they felt was prejudicial and unrelated to Grace's case. Mendenhall, one of the Scharas' attorneys, echoed similar sentiments to Scott at the press conference, saying going into a hospital involves a patient "sign(ing) their rights away." Mendenhall said despite the verdict not going in their favor, he was honored to represent the Scharas at the trial. "On day one, I pretty much said there's no hope for this case, but you have a case," Mendenhall said. "But by the time we got to trial, I think that the world had turned, and I think we did have a chance at trial. And we worked as hard as we could to get a win for the family and for Grace." Scott said he is not sure what the next step is, but the family plans to continue to fight for medical reform. The family draws ties between Grace's death and the death of Grace's brother, Travis Schara, who died by suicide in 2018. Cindy said she believes Travis' death was also influenced by an interaction of medications he was taking at the time. Cindy also said she believes patients with Down Syndrome, like Grace, are not treated justly in hospitals. "We are crushed, we are shattered, but we are not defeated, and we will continue on," Jess said tearfully at the news conference. "And we know that we will see Grace and our brother Travis again someday. I hold onto that thought of them in heaven together." Jessica Van Egeren of the Milwaukee Journal Sentinel contributed to this report. Contact Kelli Arseneau at 920-213-3721 or karseneau@ Follow her on Twitter at @ArseneauKelli. This article originally appeared on Appleton Post-Crescent: After losing lawsuit, family of Grace Schara plans to continue advocacy
Yahoo
3 hours ago
- Yahoo
Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia
Conference call and webcast on Monday, June 23, 2025 at 8:00 am EDT BALA CYNWYD, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a conference call and webcast to discuss regulatory updates for the Company's nomlabofusp clinical development program for the treatment of Friedreich's Ataxia on Monday, June 23, 2025 at 8:00 am EDT. Conference Call and Webcast DetailsTo access the webcast on Monday, June 23, 2025 at 8:00 am EDT, please visit this link to the event. To participate by phone, please dial 1-877-407-9716 (domestic) or 1-201-493-6779 (international) and refer to conference ID 13754491 or click on this link and request a return call. Following the live event, an archived webcast will be available on the 'Events & Presentations' page of the Larimar website. About Larimar TherapeuticsLarimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar's lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: Forward-Looking StatementsThis press release contains forward-looking statements that are based on Larimar's management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including but not limited to statements regarding Larimar's ability to develop and commercialize nomlabofusp and any other planned product candidates, Larimar's planned research and development efforts, including the timing of its nomlabofusp clinical trials, interactions and filings with the FDA, expectations regarding potential for accelerated approval or accelerated access and time to market and overall development plans and other matters regarding Larimar's business strategies, ability to raise capital, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing' or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others, the success, cost and timing of Larimar's product development activities, nonclinical studies and clinical trials, including nomlabofusp clinical milestones and continued interactions with the FDA; that preliminary clinical trial results may differ from final clinical trial results, that earlier non-clinical and clinical data and testing of nomlabofusp may not be predictive of the results or success of later clinical trials, and assessments; that the FDA may not ultimately agree with Larimar's nomlabofusp development strategy; the potential impact of public health crises on Larimar's future clinical trials, manufacturing, regulatory, nonclinical study timelines and operations, and general economic conditions; Larimar's ability and the ability of third-party manufacturers Larimar engages, to optimize and scale nomlabofusp's manufacturing process; Larimar's ability to obtain regulatory approvals for nomlabofusp and future product candidates; Larimar's ability to develop sales and marketing capabilities, whether alone or with potential future collaborators, and to successfully commercialize any approved product candidates; Larimar's ability to raise the necessary capital to conduct its product development activities; and other risks described in the filings made by Larimar with the Securities and Exchange Commission (SEC), including but not limited to Larimar's periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at These forward-looking statements are based on a combination of facts and factors currently known by Larimar and its projections of the future, about which it cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent Larimar's management's views only as of the date hereof. Larimar undertakes no obligation to update any forward-looking statements for any reason, except as required by law. Investor Contact:Joyce AllaireLifeSci Advisorsjallaire@ 915-2569 Company Contact:Michael CelanoChief Financial Officermcelano@ 414-2715Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
3 hours ago
- Business Upturn
Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions
Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable reduction in Activin E resulting in fat loss with muscle preservation New preclinical data demonstrate that a single dose of INHBE siRNA leads to lower inflammation of adipose tissue with strong suppression of pro-inflammatory M1 macrophages in visceral fat in DIO mice, highlighting potential mechanistic insights into the risk reduction for type 2 diabetes (T2D) and coronary artery disease (CAD) suggested by human genetics CAMBRIDGE, Mass., June 20, 2025 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the presentation of preclinical data supporting WVE-007, its GalNAc-siRNA designed to silence INHBE mRNA, an obesity target with strong evidence from human genetics. The data demonstrate the ability of Wave's long-acting GalNAc-siRNA to reduce INHBE mRNA and Activin E protein, induce weight loss mainly through reduction of fat mass, and reduce pro-inflammatory macrophage recruitment in a diet-induced obese (DIO) mouse model. The data were highlighted today in an oral presentation at the American Diabetes Association's 85th Annual Scientific Sessions, taking place June 20 to 23, in Chicago. 'These exciting preclinical data highlighted in today's presentation both recapitulate human genetics findings and continue to support the potential of WVE-007 to drive weight reduction by reducing Activin E to induce lipolysis – or fat breakdown, preferentially reducing visceral fat, and decreasing inflammation of adipose tissue – all without impacting lean muscle mass. These data suggest a highly differentiated therapeutic profile with lower visceral fat, less insulin resistance and less inflammation, supporting potential for risk reduction of T2D, CAD and other obesity-related co-morbidities,' said Erik Ingelsson, MD, PhD, Chief Scientific Officer. 'Silencing of INHBE is an entirely orthogonal mechanism from GLP-1s, which are centrally acting and impact the digestive system and central nervous system to decrease appetite. If these preclinical data translate in the clinic, WVE-007 has the potential to transform the obesity treatment paradigm by delivering healthy weight loss, preservation of muscle mass, and infrequent dosing of once or twice a year. We are evaluating WVE-007 in our ongoing INLIGHT clinical trial in adults living with overweight or obesity, and we are on track to deliver the first clinical data in the second half of this year.' Human genetics provides strong evidence for INHBE as a therapeutic target. Individuals who have a protective loss-of-function variant in one copy of the INHBE gene have a healthier cardiometabolic profile, including less abdominal fat, lower triglycerides, and lower risk of type 2 diabetes and cardiovascular disease. These heterozygous carriers also exhibit favorable associations with liver traits, including reductions in cT1 (reflecting liver inflammation and fibrosis) and ALT (reflecting liver damage), with no impact on liver fat. The oral presentation titled, 'siRNA-INHBE Silencing in Mice Recapitulates Human Genetic Data and Demonstrates Improved Healthy Weight Loss Profile,' highlighted results from studies in DIO mice that evaluated monotherapy (INHBE-siRNA alone) as well as combination (INHBE siRNA and semaglutide), and maintenance (INHBE siRNA when semaglutide treatment is discontinued) treatment settings. Key results are as follows: A single dose of INHBE-siRNA led to robust target engagement, including reduction of INHBE mRNA and Activin E protein, a lipolysis suppressor that is upregulated in obesity. Liver INHBE mRNA was strongly correlated with serum Activin E levels following INHBE-siRNA treatment. A single dose of INHBE-siRNA led to weight loss on par with semaglutide. There was a decrease in diet-induced visceral adipose mass and shrinkage of adipocytes compared with PBS treatment, supporting the restoration of healthy adipose tissue with this mechanism of action. Muscle mass was preserved. Infiltration of activated macrophages in visceral adipose was significantly decreased by a single dose of INHBE-siRNA compared with PBS controls. INHBE-siRNA also significantly reduced proinflammatory M1 macrophage (CD11c positive) recruitment while sustaining levels of anti-inflammatory M2 macrophages in visceral fat, indicating an overall shift away from a pro-inflammatory state. When administered as an add-on to semaglutide, a single dose of INHBE-siRNA doubled the amount of weight loss, highlighting potential for combination treatment. Wave's INHBE siRNA curtailed rebound weight gain when semaglutide treatment was discontinued, highlighting its potential as an off-ramp and maintenance treatment following GLP-1 treatment. The full presentation can be accessed by visiting 'Scientific Presentations' on the Investors section of the Wave Life Sciences website: About Wave Life Sciences Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave's RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave's diversified pipeline includes clinical programs in Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and Obesity, as well as several preclinical programs utilizing the company's broad RNA therapeutics toolkit. Driven by the calling to 'Reimagine Possible', Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave's science, pipeline and people, please visit and follow Wave on X (formerly Twitter) and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding our expectations for WVE-007 and the anticipated therapeutic benefits thereof; the anticipated timing of clinical data from our INLIGHT clinical trial of WVE-007; the novelty of our approach to silence INHBE mRNA in order to achieve healthy, sustainable weight loss and the potential for once- or twice-yearly dosing; the potential benefits of WVE-007 over existing obesity therapies; the potential of WVE-007's mechanism (INHBE) as a novel and unique obesity treatment to induce fat loss, preserve muscle, and drive weight loss; our understanding of our preclinical data for WVE-007 and our expectations of how such data will translate in humans; beliefs that Wave's portfolio of RNA medicines is differentiated, potentially best-in-class and potentially transformative; the broad potential of Wave's RNA medicines pipeline and oligonucleotide chemistry and any benefits that may arise as a result thereof. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release and actual results may differ materially from those indicated by these forward-looking statements as a result of these risks, uncertainties and important factors, including, without limitation, the risks and uncertainties described in the section entitled 'Risk Factors' in Wave's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as amended, and in other filings Wave makes with the SEC from time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances. Contact:Kate RauschVP, Corporate Affairs and Investor Relations +1 617-949-4827
